Fecal blood occult test in detail

Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.

Fecal Occult Blood Test (FOBT) — Detailed Overview

Definition

The fecal occult blood test (FOBT) detects blood in the stool that is not clinically apparent (i.e., not visible to the naked eye). It is distinct from gross rectal bleeding — patients with frank blood on rectal exam or who report visible rectal bleeding do not need an FOBT and require direct diagnostic evaluation.
Normal fecal blood loss is 0.5–1.5 mL/day, arising from routine shedding of intestinal epithelial cells. Commercial FOBT tests are designed to turn positive when blood loss exceeds 5–10 mL/day, corresponding to 5–10 mg hemoglobin/g of feces (assuming Hb of 15 g/dL and a daily stool weight of ~150 g).
— Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 398 — Sleisenger and Fordtran's Gastrointestinal and Liver Disease

Types of FOBT

1. Guaiac-Based FOBT (gFOBT)

Principle: Guaiac is a naturally occurring phenolic compound. Hemoglobin has pseudoperoxidase activity — it catalyzes the oxidation of guaiac by hydrogen peroxide, converting it to a blue-colored quinone compound. This color change is the positive test.
Key features:
  • Detects the pseudoperoxidase activity of heme (either as intact hemoglobin or free heme)
  • Not specific for human hemoglobin — also reacts with animal hemoglobin and plant peroxidases
  • Reagents used: guaiac, orthotoluidine, orthodianisidine, benzidine (benzidine now restricted due to carcinogenicity)
  • Reagents differ in sensitivity
Sensitivity: ~30–50% for colorectal cancer (CRC)
Limitations: High false-positive and false-negative rates depending on specimen and preparation.
— Henry's Clinical Diagnosis and Management, p. 397 — Textbook of Family Medicine 9e, p. 231

2. Fecal Immunochemical Test (FIT / iFOBT)

Principle: Uses antigen–antibody reactions specific for human hemoglobin (the globin portion). Mouse antihuman hemoglobin antibodies are typically used; some tests detect as little as 50 μg hemoglobin/g feces.
Key features:
  • Specific for human hemoglobin only — does not react with animal hemoglobin, myoglobin, or plant peroxidases
  • No dietary restrictions required
  • Not affected by vitamin C, iron supplements, or rehydration
  • Useful only for lower GI bleeding — globin is destroyed in the small intestine, so upper GI bleeding yields false negatives
  • More sensitive and specific than guaiac tests; fewer false negatives
  • Not done at point of care — requires laboratory processing
Caveat: Globin is degraded at high temperatures and with delayed testing, reducing sensitivity.
— Henry's Clinical Diagnosis and Management, p. 398 — Textbook of Family Medicine 9e, p. 231

3. Stool DNA Testing (Fecal DNA / Multi-Target)

Principle: DNA markers shed continuously from colorectal tumors are amplified by PCR from a single stool specimen. DNA is stable in stool, and minute amounts are detectable.
Advantages over guaiac testing:
  • Higher sensitivity and specificity for CRC detection
  • Detects adenomas as well as cancers
Status: Promising; further evaluation for widespread use is still ongoing.
— Henry's Clinical Diagnosis and Management, p. 398

Sources of Fecal Occult Blood

Occult blood may arise anywhere along the GI tract:
SourceExamples
Upper GIEsophageal varices, peptic ulcer disease, esophageal/gastric inflammation
Small intestineAngiodysplasias
Lower GIColorectal polyps, colorectal carcinoma, inflammatory bowel disease, hemorrhoids, anal fissures
Occult blood is often the first warning sign of GI malignancy.

Causes of False-Positive Results

CategoryExamples
DietaryRed meat, fish (myoglobin/hemoglobin), horseradish, turnips, broccoli, cauliflower, radishes, bananas, black grapes, pears, plums, artichokes, mushrooms, beets, cantaloupe
MedicationsNSAIDs, aspirin (GI mucosal irritation → bleeding), anticoagulants, colchicine, reserpine, iodine (oxidizing agent)
SpecimenStool obtained by digital rectal exam (DRE) can injure rectal mucosa
Bacterial peroxidaseBowel bacteria with peroxidase activity
Note: Ingesting 8 oz of cooked red meat daily has only a ~5% chance of producing a positive test.

Causes of False-Negative Results

CategoryExamples
Vitamin C (ascorbic acid) >250 mg/dayActs as a reducing agent, inhibits guaiac oxidation
Other antioxidantsInterfere with peroxidase reaction
Proximal/upper GI bleedingHeme is degraded before reaching the rectum, particularly relevant for guaiac tests
Delayed specimen processingDehydration of slides reduces peroxidase activity; do not delay >6 days
Intermittent tumor bleedingCRC may not bleed continuously

Patient Preparation

For 3 days before testing, patients should avoid:
  • Red meat
  • High-peroxidase vegetables (broccoli, turnips, cantaloupe, cauliflower, radishes, horseradish)
  • Aspirin and NSAIDs
  • Vitamin C (>250 mg/day)
Additional cautions:
  • Do not collect specimens within 3 days of menses or during obvious rectal bleeding or hematuria
  • Delay between slide preparation and lab testing should not exceed 6 days
  • Rehydration of dried slides increases sensitivity but decreases specificity (more false positives)
— Textbook of Family Medicine 9e, p. 231

Specimen Collection

  • Standard protocol: 3 stool samples from 3 different spontaneously passed stools (home-based testing)
  • A single DRE specimen has poor sensitivity and is not adequate for CRC screening on its own
  • A single negative FOBT from DRE does not reduce the probability of advanced neoplasia

Interpretation of Results

Positive FOBT:
  • About 2–6% of asymptomatic adults test positive
    • ~10% of positives have cancer
    • 20–30% have adenomas
    • Remainder: upper GI bleeding sources, hemorrhoids, non-neoplastic causes, or no identified source
  • Only 5–10% of positive reactions prove to be from occult malignancy
  • A positive result requires further evaluation regardless of how the specimen was obtained
Negative FOBT:
  • Does not definitively rule out colonic neoplasia
  • Patients with signs/symptoms suggestive of colon cancer require further evaluation even with a negative FOBT

Workup After a Positive FOBT

Clinical contextRecommended evaluation
CRC screening (≥50 years)Colonoscopy ± EGD
Iron deficiency anemiaEGD + colonoscopy; if both negative → capsule endoscopy (small bowel)
Positive FIT + normal colonoscopyEGD likely not necessary (FIT detects only lower GI human hemoglobin)
Further evaluation modalities include:
  • Full colonoscopy (most sensitive)
  • Flexible sigmoidoscopy + barium enema
  • Virtual colonoscopy (CT colonography)

Screening Recommendations

  • Annual FOBT (guaiac or FIT) is a recommended CRC screening method
  • U.S. Multi-Society Task Force on Colorectal Cancer: annual iFOBT + colonoscopy every 10 years in average-risk asymptomatic individuals aged ≥50 years
  • Goldman-Cecil Medicine lists high-sensitivity gFOBT and FIT as annual screening tests
— Henry's Clinical Diagnosis and Management, p. 398 — Goldman-Cecil Medicine

Special Consideration: Apt Test (Neonates)

When blood is found in a neonate's stool (typically day 2–3 of life), the Apt test distinguishes swallowed maternal blood from primary neonatal GI disease:
  • Stool is mixed with water and centrifuged
  • Supernatant + 1% NaOH (5:1 ratio)
  • Yellow-brown color → maternal blood (adult Hb denatures with alkali)
  • Remains pink → fetal blood (HbF is resistant to alkali denaturation)
Sensitivity is relatively low; results must be interpreted with caution.
— Henry's Clinical Diagnosis and Management, p. 398

Summary Comparison: gFOBT vs. FIT

FeaturegFOBTFIT
DetectsHeme pseudoperoxidaseGlobin (human-specific)
Specificity for humansNoYes
Dietary restrictionsYesNo
Affected by vitamin CYes (false negative)No
Detects upper GI bleedingYesNo (globin destroyed)
Sensitivity for CRC~30–50%Higher
Cost/availabilityLow-cost, point-of-care possibleMore expensive, lab-based
This is a shared conversation. Sign in to Orris to start your own chat.